{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-22-023254","form_type":"8-K","ticker":"LYRA","cik":"0001327273","company_name":"Lyra Therapeutics, Inc.","filed_at":"2022-11-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:50.176065+00:00","generated_at":"2026-06-22T03:03:58.971214+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Lyra Therapeutics Q3 net loss $14.8M; pauses ENLIGHTEN II enrollment for in-house mfg","bullets":["Net loss of $14.8M for Q3 2022, compared to $11.1M in Q3 2021.","Cash and equivalents $109.6M; expected to fund operations through mid-2024.","ENLIGHTEN I Phase 3 trial on track for enrollment completion mid-2023; ENLIGHTEN II paused, resuming Q3 2023.","BEACON Phase 2 trial of LYR-220 advanced to randomized stage; initial data submitted for 2023 meeting.","R&D expenses rose to $10.0M from $7.1M year-over-year due to clinical trial costs."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-22-023254","json":"https://secwatch.observer/filing/0000950170-22-023254.json","markdown":"https://secwatch.observer/filing/0000950170-22-023254.md","text":"https://secwatch.observer/filing/0000950170-22-023254.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1327273/000095017022023254/0000950170-22-023254-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1327273/000095017022023254/lyra-20221108.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T03:03:58.971214+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"50c316a55fe5bfd0780e9c971a5329c89374818a","claim":"Lyra Therapeutics, Inc. reported the third quarter ended September 30, 2022 results: net income Net loss for the quarter ended September 30, 2022 was $14.8 million.","evidence_excerpt":"On November 8, 2022, Lyra Therapeutics, Inc. (the “Company”) announced its financial results for the quarter ended September 30, 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1327273/000095017022023254/0000950170-22-023254-index.htm","confidence":0.98,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the third quarter ended September 30, 2022"},{"label":"Net income","value":"Net loss for the quarter ended September 30, 2022 was $14.8 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}